- Tytuł:
- Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
- Autorzy:
- Źródło:
- Journal of Hematology & Oncology. 16(1)
Czasopismo naukowe